专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US07129251B2 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 失效
标题翻译：亚硝化和亚硝基化H 2受体拮抗剂化合物，组合物和使用方法
公开(公告)号：US07129251B2
公开(公告)日：2006-10-31
申请号：US11180790
申请日：2005-07-14
申请人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
IPC分类号： C07D295/14 , A61K31/445 , A61P1/04
CPC分类号： C07D233/54 , C07D233/64 , C07D277/48 , C07D295/092 , C07D295/096
摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的H 2 O 2受体拮抗剂化合物，以及包含至少一种H 2受体拮抗剂化合物的新组合物，其任选被至少一个NO 和/或NO 2个基团，以及任选地，至少一种捐赠，转移或释放一氧化氮的化合物，刺激一氧化氮的内源性合成，提高内源性内皮水平的内源性松弛因子，或者是一氧化氮合酶的底物和/或至少一种非甾体抗炎药，抗酸剂，含铋试剂或抗病毒剂。本发明还描述了治疗和/或预防胃肠道疾病的方法; 改善H 2受体拮抗剂的胃保护性质; 减少溃疡复发; 促进溃疡愈合; 预防和/或治疗炎症和微生物感染，眼科疾病和病症，多发性硬化和病毒感染; 并减少或减少与使用非甾体抗炎化合物相关的胃肠道毒性。

2. 发明授权

US06869973B2 Nitrosated and nitrosylated taxanes, compositions and methods of use 失效
标题翻译：硝化和亚硝化紫杉烷，组合物和使用方法
公开(公告)号：US06869973B2
公开(公告)日：2005-03-22
申请号：US10682923
申请日：2003-10-14
申请人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Stewart K. Richardson , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Stewart K. Richardson , Tiansheng Wang
IPC分类号： A61F2/84 , A61K31/145 , A61K31/15 , A61K31/335 , A61K31/337 , A61K35/14 , A61K45/00 , A61K45/06 , A61K47/30 , A61K47/32 , A61K47/34 , A61K47/48 , A61L29/00 , A61L31/00 , A61P1/04 , A61P7/02 , A61P7/04 , A61P7/10 , A61P9/00 , A61P9/10 , A61P9/12 , A61P9/14 , A61P11/00 , A61P11/02 , A61P13/12 , A61P17/00 , A61P17/02 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/06 , A61P35/00 , A61P35/02 , A61P37/02 , A61P41/00 , A61P43/00 , C07D305/14 , C07D409/12
CPC分类号： C07D409/12 , A61K31/335 , A61K45/06 , A61K47/54 , A61K47/55 , A61K47/555 , B82Y5/00 , C07D305/14 , Y10S977/775 , Y10S977/907 , Y10S977/915 , Y10S977/926 , A61K2300/00
摘要： The present invention describes novel nitrosated and/or nitrosylated taxanes, and novel compositions comprising at least one nitrosated and/or nitrosylated taxane, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The present invention also provides novel compositions comprising at least one taxane and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The compounds and compositions of the present invention can also be bound to a matrix. The present invention also provides methods for treating or preventing cardiovascular diseases and disorders, autoimmune diseases, pathological conditions resulting from abnormal cell proliferation, polycystic kidney disease, inflammatory disease, preserving organs and/or tissues or to inhibit wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis, by administering nitrosated and/or nitrosylated taxane or parent taxanes in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的紫杉烷类，以及包含至少一种亚硝化和/或亚硝基化的紫杉烷和任选的至少一种捐赠，转移或释放一氧化氮的化合物的新型组合物，提高内源性内源水平的内皮衍生舒张因子，刺激一氧化氮的内源性合成或者是一氧化氮合酶和/或至少一种治疗剂的底物。本发明还提供了包含至少一种紫杉烷和至少一种捐赠，转移或释放一氧化氮的化合物的新型组合物，提高内源性内皮衍生的松弛因子水平，刺激一氧化氮的内源性合成或者是一氧化氮合酶的底物和/或至少一种治疗剂。本发明的化合物和组合物也可以与基质结合。本发明还提供治疗或预防心血管疾病和病症，自身免疫性疾病，由异常细胞增殖引起的病理状况，多囊肾病，炎性疾病，保存器官和/或组织或抑制伤口收缩的方法，特别是预防和/ 或治疗性再狭窄，通过将硝基化和/或亚硝基化的紫杉烷或母体紫杉烷与能够释放一氧化氮或间接地将一氧化氮递送或转移到生理条件下的靶位点的一氧化氮供体组合。

3. 发明授权

US07256205B2 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 失效
标题翻译：亚硝化和亚硝基化H 2受体拮抗剂化合物，组合物和使用方法
公开(公告)号：US07256205B2
公开(公告)日：2007-08-14
申请号：US11518231
申请日：2006-09-11
申请人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
IPC分类号： C07D277/42 , A61K31/426
CPC分类号： C07D233/54 , C07D233/64 , C07D277/48 , C07D295/092 , C07D295/096
摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的H 2 O 2受体拮抗剂化合物，以及包含至少一种H 2受体拮抗剂化合物的新组合物，其任选被至少一个NO 和/或NO 2个基团，以及任选地，至少一种捐赠，转移或释放一氧化氮的化合物，刺激一氧化氮的内源性合成，提高内源性内皮水平的内源性松弛因子，或者是一氧化氮合酶的底物和/或至少一种非甾体抗炎药，抗酸剂，含铋试剂或抗病毒剂。本发明还描述了治疗和/或预防胃肠道疾病的方法; 改善H 2受体拮抗剂的胃保护性质; 减少溃疡复发; 促进溃疡愈合; 预防和/或治疗炎症和微生物感染，眼科疾病和病症，多发性硬化和病毒感染; 并减少或减少与使用非甾体抗炎化合物相关的胃肠道毒性。

4. 发明授权

US06936627B2 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 失效
公开(公告)号：US06936627B2
公开(公告)日：2005-08-30
申请号：US10282071
申请日：2002-10-29
申请人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Tiansheng Wang
IPC分类号： C07D295/08 , A61K31/198 , A61K31/222 , A61K31/29 , A61K31/341 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/426 , A61K31/445 , A61K31/4453 , A61K31/55 , A61K45/06 , A61P1/04 , A61P17/00 , A61P27/02 , A61P27/06 , A61P27/16 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/18 , C07D233/54 , C07D233/64 , C07D277/28 , C07D277/48 , C07D277/52 , C07D295/096 , C07D307/52 , C07D233/56
CPC分类号： C07D233/54 , C07D233/64 , C07D277/48 , C07D295/092 , C07D295/096
摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.

5. 发明授权

US06656966B2 Nitrosated and nitrosylated taxanes, compositions and methods of use 失效
公开(公告)号：US06656966B2
公开(公告)日：2003-12-02
申请号：US09886494
申请日：2001-06-22
申请人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Stewart K. Richardson , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Chia-En Lin , Stewart K. Richardson , Tiansheng Wang
IPC分类号： A61K31337
CPC分类号： C07D409/12 , A61K31/335 , A61K45/06 , A61K47/54 , A61K47/55 , A61K47/555 , B82Y5/00 , C07D305/14 , Y10S977/775 , Y10S977/907 , Y10S977/915 , Y10S977/926 , A61K2300/00
摘要： The present invention describes novel nitrosated and/or nitrosylated taxanes, and novel compositions comprising at least one nitrosated and/or nitrosylated taxane, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The present invention also provides novel compositions comprising at least one taxane and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The compounds and compositions of the present invention can also be bound to a matrix. The present invention also provides methods for treating or preventing cardiovascular diseases and disorders, autoimmune diseases, pathological conditions resulting from abnormal cell proliferation, polycystic kidney disease, inflammatory disease, preserving organs and/or tissues or to inhibit wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis, by administering nitrosated and/or nitrosylated taxane or parent taxanes in combination with nitric oxide donors that are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions.

6. 发明授权

US06552047B2 H2 receptor antagonist compounds in combination with nitric oxide donors, compositions and methods of use 失效
标题翻译： H2受体拮抗剂化合物与一氧化氮供体的组合物和使用方法
公开(公告)号：US06552047B2
公开(公告)日：2003-04-22
申请号：US09441891
申请日：1999-11-17
申请人： David S. Garvey , L. Gordon Letts , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Tiansheng Wang
IPC分类号： A61K314164
CPC分类号： C07D233/54 , C07D233/64 , C07D277/48 , C07D295/092 , C07D295/096
摘要： The present invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase. The present invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的H 2受体拮抗剂化合物，以及包含至少一种任选被至少一个NO和/或NO 2基团取代的H 2受体拮抗剂化合物的新组合物，和任选的至少一种化合物，捐赠，转移或释放一氧化氮，刺激一氧化氮的内源性合成，提高内源性内源性舒张因子水平，或是一氧化氮合酶的底物。本发明还描述了治疗和/或预防胃肠道疾病的方法; 改善H2受体拮抗剂的胃保护性能; 减少溃疡复发; 促进溃疡愈合; 预防和/或治疗炎症和微生物感染，眼科疾病和病症，多发性硬化和病毒感染; 并减少或减少与使用非甾体抗炎化合物相关的胃肠道毒性。

7. 发明授权

US07332505B2 Nitrosated and nitrosylated proton pump inhibitors, compositions and methods of use 失效
标题翻译：亚硝化和亚硝化质子泵抑制剂，组合物和使用方法
公开(公告)号：US07332505B2
公开(公告)日：2008-02-19
申请号：US10866303
申请日：2004-06-14
申请人： David S. Garvey , L. Gordon Letts , Stewart K. Richardson , Sang William Tam , Tiansheng Wang
发明人： David S. Garvey , L. Gordon Letts , Stewart K. Richardson , Sang William Tam , Tiansheng Wang
IPC分类号： C07D471/04 , C07D401/12 , A61K31/437 , A61K31/4184
CPC分类号： C07D401/12 , A61K31/00 , A61K31/4184 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4706 , A61K31/506 , A61K45/06 , A61K2300/00
摘要： The present invention describes novel nitrosated and/or nitrosylated proton pump inhibitor compounds, and novel compositions comprising at least one proton pump inhibitor compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers, or releases nitric oxide, induces the production of endogenous nitric oxide or endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase, and/or at least one nonsteroidal antiinflammatory drug, selective COX-2 inhibitor, antacid, bismuth-containing reagent, acid-degradable antibacterial compound, and mixtures thereof. The present invention also provides methods for treating and/or preventing gastrointestinal disorders; facilitating ulcer healing; decreasing the recurrence of ulcers; improving gastroprotective properties, anti-Helicobacter pylon properties or antacid properties of proton pump inhibitors; decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds; treating Helicobacter pylori and viral infections. The compounds and/or compositions of the present invention can also be provided in the form of a pharmaceutical kit.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的质子泵抑制剂化合物，以及包含至少一种任选被至少一个NO和/或NO 2 2个基团取代的质子泵抑制剂化合物的新型组合物，以及任选地，至少一种捐赠，转移或释放一氧化氮的化合物诱导内源性一氧化氮或内皮衍生的松弛因子的产生，刺激一氧化氮的内源性合成或者是一氧化氮合酶的底物和/或在至少一种非甾体抗炎药，选择性COX-2抑制剂，抗酸剂，含铋试剂，酸降解抗菌化合物及其混合物。本发明还提供了治疗和/或预防胃肠道疾病的方法; 促进溃疡愈合; 减少溃疡复发; 改善胃保护性质，抗幽门螺杆菌特性或质子泵抑制剂的抗酸性; 降低或减少与使用非甾体抗炎化合物相关的胃肠道毒性; 治疗幽门螺杆菌和病毒感染。本发明的化合物和/或组合物也可以以药物试剂盒的形式提供。

8. 发明申请

US20050250758A1 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 失效
标题翻译：亚硝化和亚硝基化H 2受体拮抗剂化合物，组合物和使用方法
公开(公告)号：US20050250758A1
公开(公告)日：2005-11-10
申请号：US11180790
申请日：2005-07-14
申请人： David Garvey , L. Letts , Chia-En Lin , Tiansheng Wang
发明人： David Garvey , L. Letts , Chia-En Lin , Tiansheng Wang
IPC分类号： C07D295/08 , A61K31/198 , A61K31/222 , A61K31/29 , A61K31/341 , A61K31/397 , A61K31/40 , A61K31/401 , A61K31/4164 , A61K31/426 , A61K31/445 , A61K31/4453 , A61K31/55 , A61K45/06 , A61P1/04 , A61P17/00 , A61P27/02 , A61P27/06 , A61P27/16 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/18 , C07D233/54 , C07D233/64 , C07D277/28 , C07D277/48 , C07D277/52 , C07D295/096 , C07D307/52
CPC分类号： C07D233/54 , C07D233/64 , C07D277/48 , C07D295/092 , C07D295/096
摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.
摘要翻译：本发明描述了新的亚硝化和/或亚硝基化的H 2 O 2受体拮抗剂化合物，以及包含至少一种H 2受体拮抗剂化合物的新组合物，其任选被至少一个NO 和/或NO 2个基团，以及任选地，至少一种捐赠，转移或释放一氧化氮的化合物，刺激一氧化氮的内源性合成，提高内源性内皮水平的内源性松弛因子，或者是一氧化氮合酶的底物和/或至少一种非甾体抗炎药，抗酸剂，含铋试剂或抗病毒剂。本发明还描述了治疗和/或预防胃肠道疾病的方法; 改善H 2受体拮抗剂的胃保护性质; 减少溃疡复发; 促进溃疡愈合; 预防和/或治疗炎症和微生物感染，眼科疾病和病症，多发性硬化和病毒感染; 并减少或减少与使用非甾体抗炎化合物相关的胃肠道毒性。

9. 发明申请

US20070004788A1 Nitrosated and nitrosylated H2 receptor antagonist compounds, compositions and methods of use 失效
公开(公告)号：US20070004788A1
公开(公告)日：2007-01-04
申请号：US11518231
申请日：2006-09-11
申请人： David Garvey , L. Letts , Chia-En Lin , Tiansheng Wang
发明人： David Garvey , L. Letts , Chia-En Lin , Tiansheng Wang
IPC分类号： A61K31/426
CPC分类号： C07D233/54 , C07D233/64 , C07D277/48 , C07D295/092 , C07D295/096
摘要： The invention describes novel nitrosated and/or nitrosylated H2 receptor antagonist compounds, and novel compositions comprising at least one H2 receptor antagonist compound that is optionally substituted with at least one NO and/or NO2 group, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase and/or at least one nonsteroidal antiinflammatory drug, antacid, bismuth-containing reagent or anti-viral agent. The invention also describes methods for treating and/or preventing gastrointestinal disorders; improving gastroprotective properties of H2 receptor antagonists; decreasing the recurrence of ulcers; facilitating ulcer healing; preventing and/or treating inflammations and microbial infections, ophthalmic diseases and disorders, multiple sclerosis, and viral infections; and decreasing or reducing the gastrointestinal toxicity associated with the use of nonsteroidal antiinflammatory compounds.

10. 发明授权

US06593347B2 Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use 失效
公开(公告)号：US06593347B2
公开(公告)日：2003-07-15
申请号：US09938560
申请日：2001-08-27
申请人： Upul K. Bandarage , Qing Dong , Xinqin Fang , David S. Garvey , Gregory J. Mercer , Stewart K. Richardson , Joseph D. Schroeder , Tiansheng Wang
发明人： Upul K. Bandarage , Qing Dong , Xinqin Fang , David S. Garvey , Gregory J. Mercer , Stewart K. Richardson , Joseph D. Schroeder , Tiansheng Wang
IPC分类号： A61K31445
CPC分类号： C07D207/08 , A61K45/06 , C07C381/00 , C07C2601/14 , C07D209/28 , C07D211/22 , C07D211/26 , C07D211/54 , C07D211/62 , C07D239/47 , C07D241/06 , C07D263/20 , C07D295/088 , C07D295/185 , C07D295/192 , C07D317/32 , C07F9/4006 , C07F9/4075
摘要： The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The present invention also provides methods for treating, preventing and/or reducing inflammation, pain, and fever; decreasing or reversing the gastrointestinal, renal and other toxicities resulting from the use of nonsteroidal antiinflammatory drugs; treating and/or preventing gastrointestinal disorders; treating inflammatory disease states and disorders; and treating and/or preventing ophthalmic diseases or disorders.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式